Inhaled Pain Management

• Publication date: May 2011

As life expectancy in the developed world increases and populations age, the incidence and associated morbidity of chronic and acute pain is increasing and placing a higher level of emphasis on pain management as a quality-of-life issue for patients and their families. Responding to this trend, drug developers are increasingly turning to inhalable formulations of pain management drugs. Because it has the potential to improve drug therapy complian...

As life expectancy in the developed world increases and populations age, the incidence and associated morbidity of chronic and acute pain is increasing and placing a higher level of emphasis on pain management as a quality-of-life issue for patients and their families. Responding to this trend, drug developers are increasingly turning to inhalable formulations of pain management drugs. Because it has the potential to improve drug therapy compliance, inhaled pain drug delivery addresses a key healthcare issue – one that is particularly problematic in aging populations and developing economies. Several of these development programs involve international partnerships designed to take advantage of perceived opportunities in regional markets.


Highlights

• Analyzes and evaluates intranasal and orally inhaled pain management products and pipeline candidates and assesses the market potential for existing and probable future products
• Examines inhalation product technology issues and evolving market factors for inhaled pain management therapeutics
• Provides detailed assessments of market segments and growth prospects
• Provides market data and forecasts to 2015
• Profiles inhaled pain management market sector participants, their product development activities, business strategies, and corporate alliances and affiliations

Drug Delivery Technology Industry

Executive Summary

The Pain Management Market Opportunity

Evolution in Pain Management Guidelines
Regional Factors in Pain Management Practice
Pain Management Demand Drivers
Competitive Landscape
Factors Limiting Growth

Inhalation Technology, Platforms and Design Factors

Drug Formulations
Formulation Technologies
Excipients and Release Profiles
Oral Inhalation Device Design Factors
Dry Powder Inhalers
Metered Dose Inhalers
Nebulizers
Intranasal Inhalation
Intranasal Delivery Pharmacokinetics
Intranasal Device Characteristics
Performance Factors
Bioavailability
Dose Reproducibility
Active Compound Stability

Key Near-Term Pain Markets for Inhaled Drugs
Breakthrough Cancer Pain
Cluster Headaches
Migraine
Moderate to Severe Pain

Inhaled Pain Management Drugs - Analysis and Forecasts

Approved Drugs
AstraZeneca
GlaxoSmithKline
Mylan
Novex
Roxane
Roxro
Valeant
Development-Stage Drugs
Butorphanols
Fentanyls
Dihydroergotamines
Morphines
Perchlorperazine
Triptans

Market Factors

Usability and Patient Preferences
Regulatory Issues
Patient Compliance
The Role of CMOs/CSOs

Market Participant Profiles